TheLion.com - Forum

Date: 09/15/2011 15:38

Forum: Wall Street Pit - Msg #2184671 - List ARNA msgs

Thread #673295433 (Rec: 0)

It is important to note that the FDA expressed no concern in the CRL with heart safety like they did for qnexa and contrave. Arena conducted extensive heart safety testing in their trials understanding that there was great concern in the aftermath of the Phen-Fen debacle around the potential for heart-valve damage. Arena apparently made the agency comfortable that there was no increase in heart valve risk to patients who took lorcaserin, since there was no language in the CRL expressing any concern in this regard. Lorcaserin is the only treatment that has been recently up for review that not only doesn’t increase risk to the heart, it actually decreases it.

Share This Post:

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser crainiac: Reward | Watch | IgnoreARNA: Ignore